LILRB4 and chronic myelomonocytic leukemia: Moreover, LILRB4 expression has been correlated with a trend in increased responsiveness to hypomethylating agent (HMA) therapy in CMML and MDS, although the sample size was too small to demonstrate statistical significance [19].